{"data":{"ModuleTitle":{"label":"Module Title","value":"Company Description"},"CompanyName":{"label":"Company Name","value":"Monte Rosa Therapeutics, Inc."},"Symbol":{"label":"Symbol","value":"GLUE"},"Address":{"label":"Address","value":"645 SUMMER STREET,SUITE 102, BOSTON, Massachusetts, 02210, United States"},"Phone":{"label":"Phone","value":"+1 617 949-2643"},"Industry":{"label":"Industry","value":"Biotechnology: Biological Products (No Diagnostic Substances)"},"Sector":{"label":"Sector","value":"Health Care"},"Region":{"label":"Region","value":"North America"},"CompanyDescription":{"label":"Company Description","value":"Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates."},"CompanyUrl":{"label":"Company Url","value":"https://www.monterosatx.com"},"KeyExecutives":{"label":"Key Executives","value":[{"name":"Filip Janku","title":"Chief Medical Officer"},{"name":"Jennifer Champoux","title":"Chief Operating Officer"},{"name":"John Castle","title":"Chief Data & Information Officer"},{"name":"Markus Warmuth","title":"President, Chief Executive Officer & Director"},{"name":"Sharon Townson","title":"Chief Scientific Officer"}]}},"message":null,"status":{"rCode":200,"bCodeMessage":null,"developerMessage":null}}